Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 15, Issue 12, Pages 1367-1369
Publisher
Informa UK Limited
Online
2015-11-14
DOI
10.1586/14737140.2015.1110488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Third-line dovitinib in metastatic renal cell carcinoma
- (2014) Manuela Schmidinger LANCET ONCOLOGY
- Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms
- (2013) Magdalena Buczek et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
- (2012) Tim Eisen et al. LANCET ONCOLOGY
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
- (2012) Camillo Porta et al. ONCOLOGY
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
- (2011) Ilya Tsimafeyeu et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now